Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer : Episode 13
Opinion
Video
Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs
Author(s):
Panelists discuss how addressing unmet needs in patient selection, resistance mechanisms, and long-term outcomes can enhance the efficacy of antibody-drug conjugates in breast cancer treatment.
EP: 1.Overview of Current ADCs in Breast Cancer
EP: 2.ADCs in Breast Cancer: Mechanism of Action, and Components
EP: 3.Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials
EP: 4.Expert Perspectives on the Management of SG-Related Neutropenia
EP: 5.Navigating SG-related Diarrhea
EP: 6.Expert Insights: SG Adverse Events Management including Alopecia & Nausea
EP: 7.Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
EP: 8.Clinical Management Considerations: Pneumonitis associated with T-DXd
EP: 9.Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies
EP: 10.Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer
EP: 11.Future Perspectives on ADCs in Breast Cancer
EP: 12.Expert Insights: Investigational ADCs Safety Profiles
Now Viewing
EP: 13.Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs
Video content above is prompted by the following:
Can you share some of the biggest unmet need(s) or treatment gaps that still exist for patients with breast cancer who are receiving antibody-drug conjugates and some practice pearls you wish to share with your community colleagues?
Related Videos
Related Content
